Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01106794
Recruitment Status : Recruiting
First Posted : April 20, 2010
Last Update Posted : November 8, 2021
Sponsor:
Information provided by (Responsible Party):
Javad Nazarian, Children's National Research Institute

Brief Summary:
The purpose of this study is to prospectively collect specimens from pediatric patients with diffuse intrinsic pontine glioma or brainstem glioma, either during therapy or at autopsy, in order to characterize the molecular abnormalities of this tumor.

Condition or disease
Diffuse Intrinsic Pontine Glioma Brainstem Glioma

Detailed Description:
High grade diffuse intrinsic pontine glioma (DIPG) accounts for approximately 80% of pediatric brainstem tumors and 10% of pediatric brain tumors, and is the most lethal form of brainstem gliomas in children. There is currently no effective therapy to treat these tumors. We hypothesize that this tumor exhibits unique molecular abnormalities leading to altered RNA and protein expression. The aim of this trial is to collect specimens from pediatric patients with diffuse intrinsic pontine glioma including serum, cerebrospinal fluid, urine, brain tumor and other constitutional tissue, during therapy and/or at autopsy. Our goal is to study this tissue to characterize the genetic abnormalities that lead to tumor formation in order to identify key molecules as biomarkers which we can target to design and test new and more effective treatments.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
Actual Study Start Date : April 2010
Estimated Primary Completion Date : April 2025
Estimated Study Completion Date : April 2030


Group/Cohort
Patient samples
Fresh-frozen and fixed tumor samples, correspondent normal brain tissue samples, cerebrospinal fluid, urine, and serum samples from patients affected with diffuse intrinsic pontine glioma or brainstem glioma



Primary Outcome Measures :
  1. Genome-wide expression patterns of RNA in tumor samples, normal brainstem tissue and cerebrospinal fluid using Affymetrix gene expression profiling [ Time Frame: 5 years ]
    Collected tumor and normal samples will potentially be used for RNA genome-wide expression pattern profiling.

  2. Validation of results of the genome-wide analysis [ Time Frame: 5 years ]
    The molecular analysis done on collected samples will be validated through whole genome sequencing.

  3. Proteomic profiling of tumor, normal brainstem tissue and cerebrospinal fluid [ Time Frame: 5 years ]
    To obtain full characterization of collected samples, proteomic profiling will be done on tumor and normal samples collected.

  4. Protein expression patterns as assessed by immunohistochemistry and western blot compared to normal brainstem tissue [ Time Frame: 5 years ]
    Collected tumor and normal samples will have the immunochemistry and western blot compared to assess protein expression variation.

  5. Genome-wide analysis of tumor samples and normal brainstem tissue [ Time Frame: 5 years ]
    To obtain full characterization of collected samples, whole genome sequencing will be done on tumor and normal samples collected.

  6. In vitro and in vivo molecular analysis of collected samples [ Time Frame: 5 years ]
    Collected samples will potentially be used for in vitro analysis and generation of animal models of this tumor.


Secondary Outcome Measures :
  1. Assess aspects associated with specimen acquisition, including potential benefits and drawbacks [ Time Frame: 5 years ]
    In an effort to continue to draw knowledge from samples collected, potential benefits and drawbacks from specimen acquisition will be continuously accessed.


Biospecimen Retention:   Samples With DNA
Cerebrospinal fluid, serum, urine, brainstem tumor and constitutional tissue from patients with diffuse intrinsic pontine glioma or brainstem glioma will be collected.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Community sample
Criteria

Inclusion Criteria:

  • Patients of any age with clinical and radiologic diagnosis of diffuse intrinsic pontine glioma
  • Patients with other high-grade gliomas originating in the brainstem
  • Patients with focal gliomas (WHO grade I/II) of the brainstem

Exclusion Criteria:

  • Patients with any type of infiltrative low grade (WHO grade I and II) or high grade glioma (WHO grade III and IV) originating outside the brainstem
  • Patients harboring primary brainstem tumors with other histologic diagnoses (e.g., PNET)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01106794


Contacts
Layout table for location contacts
Contact: Javad Nazarian, PhD 202-476-6022 JNazarian@cnmc.org
Contact: Madhuri Kambhampati, MS 202-476-5198 mkambhampati@childrensnational.org

Locations
Layout table for location information
United States, District of Columbia
Children's National Medical Center Recruiting
Washington, District of Columbia, United States, 20010
Principal Investigator: Javad Nazarian, PhD         
Sub-Investigator: Roger Packer, MD         
Sub-Investigator: Suresh Magge, MD         
Sub-Investigator: Amanda L Muhs, MD         
Sponsors and Collaborators
Children's National Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Javad Nazarian, PhD Children's National Research Institute
Additional Information:
Publications of Results:

Other Publications:

Layout table for additonal information
Responsible Party: Javad Nazarian, Associate Professor, Children's National Research Institute
ClinicalTrials.gov Identifier: NCT01106794    
Other Study ID Numbers: DIPG-1
First Posted: April 20, 2010    Key Record Dates
Last Update Posted: November 8, 2021
Last Verified: November 2021
Keywords provided by Javad Nazarian, Children's National Research Institute:
diffuse intrinsic pontine glioma
DIPG
childhood brainstem glioma
pediatric brainstem glioma
brainstem glioma
BSG
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Diffuse Intrinsic Pontine Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Brain Stem Neoplasms
Infratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases